Fusobacterium Nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-immune Microenvironment
Overview
Microbiology
Authors
Affiliations
Increasing evidence links the gut microbiota with colorectal cancer. Metagenomic analyses indicate that symbiotic Fusobacterium spp. are associated with human colorectal carcinoma, but whether this is an indirect or causal link remains unclear. We find that Fusobacterium spp. are enriched in human colonic adenomas relative to surrounding tissues and in stool samples from colorectal adenoma and carcinoma patients compared to healthy subjects. Additionally, in the Apc(Min/+) mouse model of intestinal tumorigenesis, Fusobacterium nucleatum increases tumor multiplicity and selectively recruits tumor-infiltrating myeloid cells, which can promote tumor progression. Tumors from Apc(Min/+) mice exposed to F. nucleatum exhibit a proinflammatory expression signature that is shared with human fusobacteria-positive colorectal carcinomas. However, unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. Collectively, these data suggest that, through recruitment of tumor-infiltrating immune cells, fusobacteria generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression.
Gut microbiota therapy in gastrointestinal diseases.
Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman S Front Cell Dev Biol. 2025; 13:1514636.
PMID: 40078367 PMC: 11897527. DOI: 10.3389/fcell.2025.1514636.
Emerging roles of intratumoral microbiota: a key to novel cancer therapies.
Fang P, Yang J, Zhang H, Shuai D, Li M, Chen L Front Oncol. 2025; 15:1506577.
PMID: 40071093 PMC: 11893407. DOI: 10.3389/fonc.2025.1506577.
Zhao F, An R, Ma Y, Yu S, Gao Y, Wang Y Clin Transl Med. 2025; 15(3):e70273.
PMID: 40070022 PMC: 11897063. DOI: 10.1002/ctm2.70273.
Thakur B, Malaise Y, Choudhury S, Neustaeter A, Turpin W, Streutker C Nat Microbiol. 2025; .
PMID: 40033140 DOI: 10.1038/s41564-025-01938-4.
Zhang H, Li Y, Li L BMC Cancer. 2025; 25(1):368.
PMID: 40022019 PMC: 11869591. DOI: 10.1186/s12885-025-13598-y.